Clinical Trial Update: Efficacy and Safety of Concurrent PD-1 Inhibitor and Radiotherapy With Immunonutrition for Esophageal Squamous Cell Carcinoma [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating the efficacy and safety of combining a PD-1 inhibitor (sintilimab) with radiotherapy and immunonutrition for locally advanced esophagea…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Esophageal Squamous Cell Carcinoma

Drugs mentioned

• Sintilimab (sintilimab)

Snippet

Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Conditions: Locally Advanced Esophageal Squamous Cell Carcinoma, Sintilimab | Phase 2 | Status: ACTIVE_NOT_RECRUITING